Adaptive Biotechnologies Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation (ADPT) develops an immune medicine platform that harnesses the adaptive immune system to create clinical diagnostics, research tools, and therapeutic insights through high-throughput sequencing of T-cell receptors (TCRs) and B-cell receptors (BCRs); its core products and services include clonoSEQ, an FDA-cleared minimal residual disease (MRD) test for monitoring blood cancers such as multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL); immunoSEQ, a research-use-only platform for immune repertoire profiling used by academic, pharmaceutical, and biotech researchers in biomarker discovery and therapeutic development; T-Detect, a T-cell-based diagnostic platform targeting diseases like Lyme disease, Crohn's disease, multiple sclerosis, and infectious conditions; and immune medicine solutions encompassing pharma services and drug discovery partnerships. Founded in 2009 by brothers Chad Robins and Harlan Robins along with Christopher Carlson, and headquartered in Seattle, Washington, with additional facilities in South San Francisco, California, the company operates primarily in the United States, serving clinical, research, and biopharmaceutical customers focused on oncology, autoimmune disorders, and infectious diseases. Recent developments include the August 2025 termination of its multi-year collaboration with Genentech, a Roche subsidiary, which ended exclusivity obligations in oncology cell therapies and enabled recognition of approximately $41.2 million in non-cash revenue across 2025 while allowing Adaptive Biotechnologies to pivot toward digital TCR-antigen prediction models, new partnering opportunities, and a T-cell depletion program in autoimmunity; ongoing expansion of clonoSEQ adoption with projected 35% growth in fiscal 2025 test volumes; and strategic emphasis on profitability through controlled operating expenses amid $170 million in 2023 revenues and $158 million for the first nine months of 2024.
Adaptive Biotechnologies Business Separation May Unlock Greater Value
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means